KR20220008824A - 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 - Google Patents

실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20220008824A
KR20220008824A KR1020217037271A KR20217037271A KR20220008824A KR 20220008824 A KR20220008824 A KR 20220008824A KR 1020217037271 A KR1020217037271 A KR 1020217037271A KR 20217037271 A KR20217037271 A KR 20217037271A KR 20220008824 A KR20220008824 A KR 20220008824A
Authority
KR
South Korea
Prior art keywords
psilocybin
disorder
subject
hours
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217037271A
Other languages
English (en)
Korean (ko)
Inventor
데릭 존 론데스브로
크리스토퍼 브라운
줄리안 스캇 노턴
질리언 무어
헤만트 캐쉬내쓰 파틸
데이비드 이 니콜스
메건 크롤
한스 에이크 에릭손
조지 골드스미스
몰리 타비사 히키
숀 헐리
예카테리나 말리에프스카이아
린지 마우드
드러몬드 이웬 조 맥컬로치
로리 엠마 메드허스트
네이선 폴센
아슬리한 셀림베이요글루
아나이스 소울라
아만다 탄 슈시앙
마농 세실 엘리자베스 베라아트
토비아스 패트릭 웰런
라스 크리스티안 와일드
스티븐 라이트
Original Assignee
컴퍼스 패쓰파인더 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컴퍼스 패쓰파인더 리미티드 filed Critical 컴퍼스 패쓰파인더 리미티드
Publication of KR20220008824A publication Critical patent/KR20220008824A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
KR1020217037271A 2019-04-17 2020-04-17 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 Pending KR20220008824A (ko)

Applications Claiming Priority (41)

Application Number Priority Date Filing Date Title
US201962835479P 2019-04-17 2019-04-17
US201962835474P 2019-04-17 2019-04-17
US201962835484P 2019-04-17 2019-04-17
US201962835472P 2019-04-17 2019-04-17
US201962835460P 2019-04-17 2019-04-17
US201962835449P 2019-04-17 2019-04-17
US201962835458P 2019-04-17 2019-04-17
US201962835478P 2019-04-17 2019-04-17
US201962835450P 2019-04-17 2019-04-17
US201962835481P 2019-04-17 2019-04-17
US201962835480P 2019-04-17 2019-04-17
US201962835477P 2019-04-17 2019-04-17
US201962835465P 2019-04-17 2019-04-17
US201962835476P 2019-04-17 2019-04-17
US201962835464P 2019-04-17 2019-04-17
US201962835485P 2019-04-17 2019-04-17
US201962835482P 2019-04-17 2019-04-17
US62/835,449 2019-04-17
US62/835,480 2019-04-17
US62/835,481 2019-04-17
US62/835,477 2019-04-17
US62/835,460 2019-04-17
US62/835,465 2019-04-17
US62/835,464 2019-04-17
US62/835,479 2019-04-17
US62/835,450 2019-04-17
US62/835,472 2019-04-17
US62/835,484 2019-04-17
US62/835,474 2019-04-17
US62/835,458 2019-04-17
US62/835,478 2019-04-17
US62/835,476 2019-04-17
US62/835,485 2019-04-17
US62/835,482 2019-04-17
US201962893110P 2019-08-28 2019-08-28
US62/893,110 2019-08-28
US201962893611P 2019-08-29 2019-08-29
US62/893,611 2019-08-29
US201962946159P 2019-12-10 2019-12-10
US62/946,159 2019-12-10
PCT/IB2020/053687 WO2020212951A1 (en) 2019-04-17 2020-04-17 Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Publications (1)

Publication Number Publication Date
KR20220008824A true KR20220008824A (ko) 2022-01-21

Family

ID=70465167

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217037271A Pending KR20220008824A (ko) 2019-04-17 2020-04-17 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
KR1020217037272A Pending KR20220009954A (ko) 2019-04-17 2020-04-17 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR1020217037273A Pending KR20220009955A (ko) 2019-04-17 2020-04-17 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217037272A Pending KR20220009954A (ko) 2019-04-17 2020-04-17 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
KR1020217037273A Pending KR20220009955A (ko) 2019-04-17 2020-04-17 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료

Country Status (9)

Country Link
US (9) US12377112B2 (https=)
EP (3) EP3955936A1 (https=)
JP (6) JP2022529476A (https=)
KR (3) KR20220008824A (https=)
CN (3) CN113993523A (https=)
AU (3) AU2020258086B2 (https=)
CA (3) CA3138094A1 (https=)
TW (1) TW202103699A (https=)
WO (3) WO2020212952A1 (https=)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20230368919A1 (en) * 2017-11-30 2023-11-16 Viewmind, Inc. Method for identifying specific alterations in subjects with defined diseases analyzing oculomotor patterns when using specific visual stimuli, where a specific drug or treatment would enhance visual processing, cognitive performance and related brain activities
JP7389421B2 (ja) * 2018-07-13 2023-11-30 Ｐｓｔ株式会社 精神・神経系疾患を推定する装置
CA3132731A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
US12377112B2 (en) * 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20220233133A1 (en) * 2019-05-22 2022-07-28 President And Fellows Of Harvard College Human tactile prepulse inhibition assay
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
CA3152752A1 (en) 2019-10-01 2021-04-08 Thomas Henley Genetic engineering of fungi to modulate tryptamine expression
WO2021072530A1 (en) * 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Controlled release formulations of psilocybe-derived agents and method for their use, and methods and compositions for threating mild traumatic brain injury with post traumatic stress disorder.
CA3160793A1 (en) * 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
US20210237064A1 (en) 2020-01-31 2021-08-05 Astrin Biosciences, Inc. Biological Fluid Filtration System
JP2023515616A (ja) * 2020-02-28 2023-04-13 ユニヴェルシテートスピタル バーゼル ５ｈｔ２ａアゴニストの投与後の抑制効果
CA3175211A1 (en) * 2020-04-13 2021-10-21 Matthias Emanuel LIECHTI Lsd dose identification
EP4135713A4 (en) * 2020-04-17 2024-04-17 Revive Therapeutics Ltd. Use of psilocybin in the treatment of neurological brain injury and migraines
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12059533B1 (en) * 2020-05-20 2024-08-13 Pineal Labs Inc. Digital music therapeutic system with automated dosage
WO2021243460A1 (en) * 2020-06-03 2021-12-09 Neonmind Biosciences Inc. Method for weight loss with therapy
WO2021243461A1 (en) * 2020-06-04 2021-12-09 Neonmind Biosciences Inc. Use of lsd, esa, or dmt for weight loss.
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
EP4178569A4 (en) * 2020-07-10 2024-07-31 Eleusis Therapeutics US, Inc. Method of treatment for psilocybin or psilocin infusion
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
CA3193308A1 (en) 2020-10-21 2022-04-28 Compass Pathfinder Limited Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
WO2022115796A1 (en) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating neurological conditions
WO2022115798A2 (en) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions and methods for treating migraine
WO2022123232A1 (en) * 2020-12-07 2022-06-16 Beckley Psytech Limited Pharmaceutical composition comprising psilocybin or its polymorphs
WO2022125949A1 (en) * 2020-12-13 2022-06-16 Silo Pharma, Inc. Use of psilocybin in cancer treatment
AU2021407382A1 (en) * 2020-12-21 2023-08-10 Psilobrain Therapeutics Inc. Compositions and methods for anxiety disorder treatment
CN116963742A (zh) * 2021-01-08 2023-10-27 纽约大学 用赛洛辛或赛洛西宾治疗自杀倾向
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
WO2022178008A1 (en) * 2021-02-16 2022-08-25 Augusta University Research Institute, Inc. Cannabidiol for treating neurodegenerative diseases
US20220273628A1 (en) * 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
US20220265582A1 (en) * 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
CA3212065A1 (en) * 2021-03-15 2022-09-22 James Gilligan Improved methods for the use of psychedelics
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
CA3113414A1 (en) * 2021-03-29 2022-09-29 Mind Cure Health Inc. Psychedelics protocol computer systems and methods
US20250281513A1 (en) * 2021-03-30 2025-09-11 Mynd Life Sciences Inc. Use of psychedelics to treat dementia
TW202304466A (zh) 2021-03-30 2023-02-01 英商康派斯開拓者公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法
EP4329759A4 (en) 2021-04-30 2025-07-16 Mind Medicine Inc CRYSTALLINE FORMS OF LSD SALTS
WO2022235500A1 (en) * 2021-05-03 2022-11-10 Mind Medicine, Inc. Psychedelics for treatment of pain
US12611399B2 (en) 2021-05-04 2026-04-28 Definium Therapeutics US, Inc. Movement disorders
KR20240009433A (ko) * 2021-05-17 2024-01-22 사이빈 아이알엘 리미티드 실로시빈의 제형
CA3218110A1 (en) 2021-05-25 2022-12-01 Majed Fawaz New n,n-dimethyltryptamine salts and crystalline salt forms
WO2022265878A1 (en) * 2021-06-14 2022-12-22 Mind Medicine, Inc. Controlling effects after 5ht2a agonists administration
AU2022309017A1 (en) 2021-07-07 2024-01-25 Terran Biosciences Inc. N,n-dimethyltryptamine and related psychedlics and uses thereof
US20240293082A1 (en) * 2021-07-09 2024-09-05 Cybin Irl Limited Integrated data collection devices for use in various therapeutic and wellness applications
WO2023012524A2 (en) * 2021-08-03 2023-02-09 Universitatsspital Basel Lsd and psilocybin dose equivalence determination
JP7846211B2 (ja) 2021-08-19 2026-04-14 デフィニウム セラピューティクス ユーエス， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
JP2024533291A (ja) * 2021-09-08 2024-09-12 サイビン アイアールエル リミテッド 併用薬物療法
US20240424005A1 (en) * 2021-11-08 2024-12-26 Nova Mentis Life Science Corp. DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASE WITH PSYCHOACTIVE TRYPTAMINE DERIVATIVES AND mRNA MEASUREMENTS
WO2023086252A1 (en) * 2021-11-09 2023-05-19 Compass Pathfinder Limited Treatment of treatment resistant depression with psilocybin
US20250011351A1 (en) 2021-11-12 2025-01-09 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
WO2023086962A1 (en) * 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybin and o-acetylpsilocin, salts and solid state forms thereof
CA3238027A1 (en) * 2021-11-23 2023-06-01 Compass Pathfinder Limited Intelligent transcription and biomarker analysis
CA3240578A1 (en) * 2021-12-10 2023-06-15 GATC Health Corp Methods of treating ptsd and neurological disorders
EP4447948A1 (en) * 2021-12-13 2024-10-23 COMPASS Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
CN118984868A (zh) 2021-12-31 2024-11-19 恩派瑞安神经科学公司 用于产生精神药物生物碱的遗传修饰的生物体
WO2023135595A1 (en) * 2022-01-11 2023-07-20 Psyrx Ltd. Combinations with psilocybin for treating gastrointestinal diseases or disorders
WO2023137325A1 (en) * 2022-01-11 2023-07-20 New York University Treating alcohol use disorder using psilocybin
WO2023164092A1 (en) * 2022-02-25 2023-08-31 Parow Entheobiosciences Llc Treatment of psychiatric disorders, brain injuries, and autism spectrum disorder
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
WO2023186837A1 (en) * 2022-03-27 2023-10-05 GH Research Ireland Limited Treatment of postnatal depression
IL315899A (en) * 2022-03-27 2024-11-01 Gh Res Ireland Limited 5-METHOXY-N,N-DIMETHYLTRYPTamine for the treatment of social/emotional withdrawal or withdrawal
AU2023242469A1 (en) * 2022-03-31 2024-09-05 Cybin Irl Limited Combination of nitrous oxide and 5-ht2a receptor agonists
WO2023215344A2 (en) * 2022-05-03 2023-11-09 Wesana Health Inc. Compositions and methods for treating cluster-tic syndrome
WO2023215342A1 (en) * 2022-05-03 2023-11-09 Wesana Health Inc. Compositions and methods for treating trigeminal neuralgia
US20250352563A1 (en) * 2022-05-03 2025-11-20 Revive Therapeutics Ltd Method and Use of Psilocybin in the Prevention and Treatment of Stroke
WO2023215338A1 (en) * 2022-05-03 2023-11-09 Wesana Health Inc. Compositions and methods for treating cluster headache
EP4518971A4 (en) * 2022-05-05 2026-04-29 Ananda Scient Inc SYSTEM AND METHOD FOR MANAGING RELATIONSHIPS, ORGANIZING, RETRIEVING AND SHARING DIFFERENT TYPES OF CONTENT
US20250114383A1 (en) * 2022-05-13 2025-04-10 Reset Pharmaceuticals, Inc. Administration of a psychedelic compound by intravenous infusion
JP2025521221A (ja) * 2022-06-08 2025-07-08 ティーアールワイピー セラピューティクス インコーポレイテッド 精神拡張薬を用いた過食性障害の治療
IL315086A (en) 2022-06-09 2024-10-01 Diamond Therapeutics Inc Amorphous (A-polymorphic) psilocybin
WO2023247665A1 (en) 2022-06-22 2023-12-28 Cybin Irl Limited Solid dispersions of psilocybin
US20240000795A1 (en) * 2022-06-30 2024-01-04 Terran Biosciences Inc. Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
WO2024019908A1 (en) * 2022-07-19 2024-01-25 Lobe Sciences Ltd. Serotonergic psychedelic agent for treating selective mutism
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
GB202214721D0 (en) * 2022-10-06 2022-11-23 Rewire Therapeutics Ltd A treatment for mental disorders
WO2024079648A1 (en) * 2022-10-11 2024-04-18 Sintalica S.R.L. Delivery system for the controlled release of psychedelic compound, pharmaceutical composition and uses thereof
CN120897742A (zh) * 2022-11-15 2025-11-04 福睿德姆生物科学公司 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效
IL321485A (en) * 2022-12-14 2025-08-01 Luminous Mind Inc Treatment of psychological symptoms affecting other medical conditions (PFAOMC)
EP4673125A1 (en) * 2023-02-28 2026-01-07 Mind Medicine, Inc. R-mdma for treatment of pain
CN121285372A (zh) * 2023-04-28 2026-01-06 耶鲁大学 治疗创伤后应激障碍的组合物和方法
AU2024267304A1 (en) * 2023-05-11 2026-01-08 Spiritus Bioscience, Inc. Sublingual spray formulations of psychedelics
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
JP7608525B1 (ja) 2023-06-27 2025-01-06 株式会社キャタラー ガソリンエンジン用排ガス浄化触媒装置
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12180158B1 (en) 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine
WO2025038542A1 (en) * 2023-08-11 2025-02-20 The Regents Of The University Of California Psilocybin for treating phantom pain
CN117695377B (zh) * 2023-12-14 2025-01-07 贵州医科大学 Vsig2在制备治疗自身免疫性疾病产品中的应用

Family Cites Families (510)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA672478A (en) 1963-10-15 Heim Roger Psilocybin and psilocin
LU36879A1 (https=) 1958-02-21
GB911946A (en) 1958-02-21 1962-12-05 Sandoz Ltd Psilocybin and psilocin and processes for their preparation
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
BE582353A (https=) 1958-09-12
US3192111A (en) * 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
IE24138L (en) 1959-02-18 1959-08-21 Sandoz Ag Psilocybin and psilocin
JPS5576859A (en) 1978-12-01 1980-06-10 Fujimoto Seiyaku Kk Novel preparation of 4-hydroxyindole
JPS5728046A (en) 1980-07-28 1982-02-15 Nissan Chem Ind Ltd Preparation of 4-substituted indole
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
IL76591A0 (en) 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US5785989A (en) 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
DE3689927T3 (de) 1985-10-04 1998-10-22 South African Inventions Reagens und Verfahren.
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
WO1991003233A1 (en) 1989-09-05 1991-03-21 University Of Utah Research Foundation Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5935925A (en) 1990-05-08 1999-08-10 Synaptic Pharmaceutical Corporation Methods of treating migraine and compounds useful for such methods
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
DE69133205T2 (de) 1990-10-19 2003-12-11 New York University, New York Eine methode zur transplantation von zellen in das gehirn und ihre therapeutische verwendung
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
FR2675504B1 (fr) 1991-04-16 1995-01-27 Delalande Sa Derives d'aryl-3 oxazolidinone, leur procede de preparation et leur application en therapeutique.
US5468486A (en) 1992-01-21 1995-11-21 The University Of Tennessee Research Corporation Vaccine containing a protein alkaloid conjugate for the treatment of fescue toxicosis
EP0566135A1 (en) 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
EP0628042B1 (en) 1992-12-24 2001-08-16 PHARMACIA & UPJOHN S.p.A. Serotoninergic ergoline derivatives
ES2068762B1 (es) 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US20060019963A1 (en) 1994-06-17 2006-01-26 Smithkline Beecham Corporation Compounds
ATE324897T1 (de) 1994-07-25 2006-06-15 Nda Int Inc Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern
US5874477A (en) 1994-08-12 1999-02-23 The University Of Hawaii Method of treatment for malaria utilizing serotonin receptor ligands
US5696125A (en) 1995-02-24 1997-12-09 Research Foundation Of The State University Of New York Substance abuse-induced hemorrhagic stoke in an animal model
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
MX9700850A (es) 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5879690A (en) 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
DE19542281C2 (de) 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
FR2744361B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744364B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application d'ureidoacetamides a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744363B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de thiazolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
FR2744362B1 (fr) 1996-02-07 1998-02-27 Rhone Poulenc Rorer Sa Application de derives de pyrrolidine a la preparation de medicaments destines au traitement de l'abus de drogues ou de substances donnant lieu a des pharmacomanies ou a un usage excessif
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
TW448171B (en) 1996-06-06 2001-08-01 Yamanouchi Pharma Co Ltd Imidazole-substituted quinoxalinedione derivatives
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
US5958919A (en) 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US5891885A (en) 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5804592A (en) 1997-05-30 1998-09-08 Unimed Pharmaceuticals, Inc. Method for improving disturbed behavior and elevating mood in humans
JP2002501510A (ja) 1997-05-07 2002-01-15 ユニメッド・ファーマシューティカルズ・インコーポレーテッド ヒトにおける攪乱行動を改善し気分を高揚させる方法
US6558956B1 (en) 1997-06-24 2003-05-06 The University Of Wyoming Method and apparatus for detection of a controlled substance
GB9715082D0 (en) 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
US7799337B2 (en) 1997-07-21 2010-09-21 Levin Bruce H Method for directed intranasal administration of a composition
US20010004644A1 (en) 1997-07-21 2001-06-21 Levin Bruce H. Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation
AU8915598A (en) 1997-08-25 1999-03-16 Pentech Pharmaceuticals, Inc. Method for amelioration of social phobia
ATE265213T1 (de) 1997-09-04 2004-05-15 Novoneuron Inc Noribogain zur behandlung von schmerzen und drogenabhängigkeit
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
DE19738855C2 (de) 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6228864B1 (en) 1997-10-28 2001-05-08 Vivus, Inc. Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction
US5922341A (en) 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
ITTO980264A1 (it) 1998-03-26 1999-09-26 Silvio Rossi Applicazione di un estratto basico non quaternario della peschiera fuchsiaefolia ad attivita' antimalarica
WO1999066909A2 (en) 1998-06-22 1999-12-29 Univ Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
AU4984899A (en) 1998-07-14 2000-02-07 Adams Food Ltd. Nutritionally active composition for hardening fingernails
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
CA2337507A1 (en) 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
MXPA01001180A (es) 1998-07-31 2002-04-24 Vela Pharmaceuticals Inc Metodos y composiciones para el tratamiento y la prevencion de abuso de sustancias empleando moclobemida.
ATE310566T1 (de) 1998-09-18 2005-12-15 Alcon Mfg Ltd 5ht2-agoniste zur behandlung des glaukoms
US20060025387A1 (en) 1998-12-23 2006-02-02 Cytoscan Sciences Llc Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
DE59905248D1 (de) 1999-01-29 2003-05-28 Disphar Int Bv Pharmazeutische zusammensetzungen
ATE294577T1 (de) 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
CA2368187A1 (en) 1999-03-19 2000-09-28 Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2000059479A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
ID30355A (id) 1999-04-07 2001-11-22 Pfizer Prod Inc Penggunaan inhibitor-inhibitor cyp2d6 dalam terapi kombinasi
US6126924A (en) 1999-05-27 2000-10-03 Scales-Medeiros; Virginia A. Light responsive self-tanning products and methods for use
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US6489341B1 (en) 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
CA2382666A1 (en) 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation of the blood-brain barrier transporter for leptin
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
AU8003800A (en) 1999-10-08 2001-04-23 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
ES2162746B1 (es) 1999-10-21 2003-02-16 Lipotec Sa Microcapsulas para la estabilizacion de productos cosmeticos, farmaceuticos o de alimentacion.
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20030096831A1 (en) 2000-01-18 2003-05-22 Stone Richard A. Ocular growth and nicotinic antagonists
RU2002120485A (ru) 2000-01-18 2004-04-10 Волли Фордж Фармасьютикл, Инк. (Us) Глазной рост и никотиновые антагонисты
FR2804603B1 (fr) 2000-02-04 2004-01-23 Rhodia Chimie Sa Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
AU2001243369A1 (en) 2000-03-14 2001-09-24 Massachusetts Institute Of Technology Composition and method to treat weight gain and obesity attributable to psychotropic drugs
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
EP1278774A2 (en) 2000-03-27 2003-01-29 PE Corporation (NY) Human g-protein coupled receptors
US6380176B2 (en) 2000-03-28 2002-04-30 Ajinomoto Co., Inc. Method for inhibiting non-intentional behavior with a running neuron inhibitory substance
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
WO2001082915A2 (en) 2000-04-28 2001-11-08 Neal Gary W Trans-clitoral administration of therapy
JP4763957B2 (ja) 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
WO2002005849A2 (en) 2000-07-19 2002-01-24 Pitmy International N.V. Transportation of nucleic acid substances
EP1409530A2 (en) 2000-09-19 2004-04-21 Microbia, Inc. Modulation of secondary metabolite production by zinc binuclear cluster proteins
US9474776B2 (en) 2000-10-04 2016-10-25 Paul Edward Stamets Integrative fungal solutions for protecting bees
US9399050B2 (en) 2000-10-04 2016-07-26 Paul Edward Stamets Controlling insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi
US20030119884A1 (en) 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
US20070100000A1 (en) 2000-11-01 2007-05-03 Epstein Mel H Methods of providing neuroprotection
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
CA2430298A1 (en) 2000-11-30 2002-06-06 Banavara Lakshman Mylari Combination of gaba agonists and sorbitol dehydrogenase inhibitors
WO2002043763A2 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20020137785A1 (en) 2001-03-26 2002-09-26 George Kindness Inflammatory mechanism modulator composition and methods with anti-asthmatic properties
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU2002305123B2 (en) 2001-03-30 2006-10-05 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US20040132780A1 (en) 2001-05-04 2004-07-08 Allen Christopher P. Method and compositions for treating migraines
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20040023952A1 (en) 2001-06-20 2004-02-05 Leventhal Audie G. Enhanced brain function by gaba-ergic stimulation
WO2003016903A2 (de) 2001-08-20 2003-02-27 Walter Pils Vorrichtung und verfahren zum nachweis eines analyten
US6541043B2 (en) 2001-08-28 2003-04-01 Dexgen Pharmaceuticals, Inc. Method and synergistic composition for treating attention deficit/hyperactivity disorder
EP1429728A1 (en) 2001-08-29 2004-06-23 SRL Technologies, Inc. Sustained release preparations
CA2492823A1 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
KR20040039436A (ko) 2001-09-27 2004-05-10 파마시아 에이비 약학 조성물
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US6592901B2 (en) 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US20060264508A1 (en) 2001-10-16 2006-11-23 Stone Richard A Modulation of ocular growth and myopia by gaba drugs
US20030082225A1 (en) 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
EP1453468A4 (en) 2001-11-09 2005-11-23 Chiron Corp METHOD OF VACCINATION OF A HUMAN PATIENT TO PREVENT METASTATIC TUMORS
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7241797B2 (en) 2002-01-23 2007-07-10 University Of Cincinnati Method of increasing milk production
US20030171435A1 (en) 2002-01-23 2003-09-11 Drug Abuse Sciences, Inc. New amphetamine derivatives, antibodies against them and pharmaceutical compositions containing them
WO2003066029A2 (en) 2002-02-07 2003-08-14 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
ATE346591T1 (de) 2002-02-07 2006-12-15 Pharmacia Corp Pharmazeutische tablette
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US7700561B2 (en) 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
US20030199439A1 (en) 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
CN1662231A (zh) 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
AU2003228654A1 (en) 2002-04-29 2003-11-17 The General Hospital Corporation Compositions and methods for preventing abuse of orally administered medications
AUPS317102A0 (en) 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
JP2005537244A (ja) 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
US20040006043A1 (en) 2002-07-02 2004-01-08 Ramot University Authority For Applied Research & Industrial Development Ltd. Methods, pharmaceutical compositions and pharmaceutical kits for enhancing the therapeutic efficiency of cancer chemotherapeutic agents
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
CA2487849A1 (en) 2002-07-18 2004-01-29 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
JPWO2004014429A1 (ja) 2002-08-09 2005-12-02 三菱ウェルファーマ株式会社 精神疾患発症脆弱性制御剤
US20030114512A1 (en) 2002-09-09 2003-06-19 Collier Robert J Compounds with 5-ht2 and 5-ht1a agonist activity for treating glaucoma
AU2003278832A1 (en) 2002-09-13 2004-04-30 Carnegie Mellon University Optical biosensors and methods of use thereof
WO2004026290A1 (en) 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
DE10244504A1 (de) 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
CN1703199B (zh) 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
WO2004111185A2 (en) 2002-10-30 2004-12-23 The Regents Of The University Of California Direct micro-patterning of lipid bilayers using uv light and selected uses thereof
DE10250944B9 (de) 2002-10-31 2004-09-16 Cell Center Cologne Gmbh Verwendung eines Stifts zur Applikation von Pflege- oder Wirkstoffen in die Nase
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
PT1587789E (pt) 2003-01-16 2008-12-16 Acadia Pharm Inc Agonistas inversos selectivos para receptores 2a/2c da serotonina como agentes terapêuticos para doenças neurodegenerativas
JP2006515628A (ja) 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
US20040186155A1 (en) 2003-01-30 2004-09-23 Dayno Jeffrey Marc Combination therapy for the treatment or prevention of migraine
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
DK1610796T3 (da) 2003-03-17 2014-07-21 Neurohealing Pharmaceuticals Inc Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc Abuse resistant amphetamine compounds
EP1635815A4 (en) 2003-06-03 2009-03-25 Beth Israel Hospital METHOD AND COMPOUNDS FOR TREATING TISSUE TESTS
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
JP4174016B2 (ja) 2003-07-11 2008-10-29 株式会社ビーエル 競合法によるサイロシン類のイムノクロマトグラフィー検出法及びテストキット
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US20050203011A1 (en) 2003-09-19 2005-09-15 The Regents Of The University Of California Mitigating symptoms and behaviors of substance abuse by modulating GDNF or BDNF pathway activity
US20050070501A1 (en) 2003-09-29 2005-03-31 New York Blood Center, Inc. Water dispersible film
JP4641942B2 (ja) 2003-10-03 2011-03-02 フェーイレン・ナムローゼ・フェンノートシャップ ヒトおよび動物におけるｉｇｆ−１血清レベルの低下と関連した種々の疾患状態の治療用の治療用組成物の製造のための血清中ｉｇｆ−１レベルを増加できる化合物の使用
WO2005037199A2 (en) 2003-10-10 2005-04-28 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US20070053954A1 (en) 2003-10-24 2007-03-08 Rowe Stephen C Macromer-melt formulations
CA2585024A1 (en) 2003-10-24 2005-05-06 Azopax Therapeutics Llc Macromer-melt formulations
JP2005132747A (ja) 2003-10-29 2005-05-26 Ajinomoto Co Inc 老齢伴侶動物の老化行動改善剤
EP1701725B1 (en) 2003-12-16 2013-07-31 Relevare Aust. Pty Ltd Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain
US20050260258A1 (en) 2003-12-18 2005-11-24 The Texas A&M University System Use of vitelline protein B as a microencapsulating additive
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
GB0400802D0 (en) 2004-01-14 2004-02-18 Daniolabs Ltd Compounds for the treatment of disease
EP1715843A1 (en) 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
WO2005079756A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005079773A2 (en) 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
US7981441B2 (en) 2004-02-18 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Drug delivery systems using mesoporous oxide films
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
FR2867075B1 (fr) 2004-03-03 2006-07-14 Ethypharm Sa Procede de preparation de microspheres biodegradables calibrees
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
EP1737473A4 (en) 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
WO2005102390A2 (en) 2004-04-22 2005-11-03 Pfizer Japan, Inc. Combinations comprising alpha-2-delta ligands and nmda receptor antagonists
RU2253461C1 (ru) 2004-04-30 2005-06-10 Общество с ограниченной ответственностью "Паркинфарм" Фармацевтическая комбинация, оказывающая влияние на функционирование цнс, способ коррекции состояний, связанных с нарушениями функционирования цнс; фармацевтический набор; средство, способствующее проникновению через гематоэнцефалический барьер лекарственных субстанций и метаболитов; фармацевтическое средство для эндоназального применения
US20050255091A1 (en) 2004-05-14 2005-11-17 Loomis Gary L Hydrogels for biomedical applications
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US20050265955A1 (en) 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
NL1026634C2 (nl) 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychofarmaceutisch preparaat en werkzame stof daarin.
US7799802B2 (en) 2004-08-03 2010-09-21 Institstute of Oriental Medical Science Inc. Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation
US20060030625A1 (en) 2004-08-06 2006-02-09 Cheryle Ram Hart Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
US20060045865A1 (en) 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
EP2347765B1 (en) 2004-09-24 2014-01-22 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy
US7655691B2 (en) 2004-09-27 2010-02-02 Sard Howard P Indole compounds useful as serotonin selective agents
US20060240043A1 (en) 2004-10-08 2006-10-26 Meyerson Laurence R Methods and compositions for treating migraine pain
AU2005306579B2 (en) 2004-11-22 2012-01-19 Immuron Limited Bioactive compositions
FR2878161B1 (fr) 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2878158B1 (fr) 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
US7294649B2 (en) 2004-12-17 2007-11-13 Roche Diagnostics Operatins, Inc. Methamphetamine derivatives and conjugates for immunoassay
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US20060192098A1 (en) 2005-01-10 2006-08-31 Smiths Detection Inc. Sampling swab
DE102005004343A1 (de) 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
ES2573539T3 (es) 2005-03-21 2016-06-08 Teva Czech Industries S.R.O. Inhibidor de la cristalización y su uso en cápsulas de gelatina
ES2391030T3 (es) 2005-03-23 2012-11-20 Bpsi Holdings, Llc. Composiciones de almidón aglomerado
EP1863454A2 (en) 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of migraine
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
BRPI0612440A2 (pt) 2005-04-08 2010-11-23 New River Pharmaceuticals Inc composição farmacêutica e uso de um profármaco de anfetamina
JP2008536866A (ja) 2005-04-15 2008-09-11 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ アミン作動性医薬組成物および方法
WO2007004067A2 (en) 2005-04-15 2007-01-11 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
CA2605580A1 (en) 2005-04-22 2006-11-02 Wyeth Benzodioxane and benzodioxolane derivatives and uses thereof
EP1877382B1 (en) 2005-05-06 2012-11-28 Smiths Detection Inc. Method of using isobutyramide as an ionization reagent in IMS-spectrometry
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
GB0511060D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CA2610838A1 (en) 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
CA2612309C (en) 2005-06-16 2014-12-16 Mohammed Saeed Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070092586A1 (en) 2005-10-26 2007-04-26 Alamo Pharmaceuticals Compositions and methods for the administration psychotropic drugs which modulate body weight
DE102005055866A1 (de) 2005-11-23 2007-05-24 Hte Ag The High Throughput Experimentation Company Verfahren zur Herstellung von Aryl-Aryl gekoppelter Verbindungen
KR20080089653A (ko) 2006-01-21 2008-10-07 애보트 게엠베하 운트 콤파니 카게 남용 약물의 전달을 위한 투여형 및 방법
CN101336116B (zh) 2006-02-02 2013-01-02 医学技术设备公司 一种包含溶胶-凝胶组合物的生物活性物质输送系统
US20070203216A1 (en) 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20070190130A1 (en) 2006-02-16 2007-08-16 Mark William A Protein hydrolysate excipients
US20080075789A1 (en) 2006-02-28 2008-03-27 The Regents Of The University Of California Genes differentially expressed in bipolar disorder and/or schizophrenia
CA2644311C (en) 2006-03-01 2012-07-10 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
FR2898271B1 (fr) 2006-03-09 2009-01-16 Pierre Fabre Medicament Sa Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2006079999A2 (en) 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
JP2009533519A (ja) 2006-04-14 2009-09-17 インターフェース バイオロジクス，インコーポレーテッド グラフトポリマーおよびその使用
GB0608647D0 (en) 2006-05-02 2006-06-14 Haritou Susan J A Methods of diagnosis and treatment
ES2529455T3 (es) 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
WO2008003028A2 (en) 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
WO2008053362A2 (en) 2006-06-30 2008-05-08 Interface Biologics, Inc. Bioresponsive polymers
WO2008010223A2 (en) 2006-07-17 2008-01-24 Ramot At Tel Aviv University Ltd. Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use in treating pain and other cns disorders
US20090312306A1 (en) 2006-07-20 2009-12-17 Guangri Sun Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
US20080026189A1 (en) 2006-07-27 2008-01-31 Chun-Wei Lin Thin key structure for generating dazzling light
BRPI0715633A2 (pt) 2006-08-23 2013-07-02 Univ Montana mÉtodo de reduÇço de dano em cÉlula neuronal
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008026046A1 (en) 2006-08-30 2008-03-06 Pfizer Products Inc. Morpholine d3 dopamine antagonists
EP2081429A4 (en) 2006-08-31 2010-01-06 Biogen Idec Inc PROCESS FOR PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
AU2007299920A1 (en) 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
EP2083825A4 (en) 2006-09-26 2009-11-04 Addiction Res Inst Inc HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS
WO2008038291A1 (en) 2006-09-27 2008-04-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
WO2008051599A2 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
MX2009004552A (es) 2006-10-27 2009-11-10 Janssen Pharmaceutica Nv Metodos de tratamiento de trastornos de comportamiento perturbador.
MX2009004798A (es) 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
US8653106B2 (en) 2010-07-30 2014-02-18 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US9823737B2 (en) * 2008-04-07 2017-11-21 Mohammad A Mazed Augmented reality personal assistant apparatus
US10529003B2 (en) * 2008-04-07 2020-01-07 Mohammad A. Mazed Optical biomodule for detection of diseases at an early onset
WO2008073918A1 (en) 2006-12-11 2008-06-19 Kempharm, Inc. Non-standard amino acid conjugates of amphetamine and processes for making and using the same
ES2302650B1 (es) 2007-01-11 2009-02-16 Tedec-Meiji Farma, S.A. Composicion de rapida desintegracion en la cavidad bucal.
US20100076006A1 (en) 2007-01-31 2010-03-25 University Of Virginia Patent Foundation Topiramate Plus Naltrexone for the Treatment of Addictive Disorders
AU2008213643A1 (en) 2007-02-08 2008-08-14 Kempharm, Inc. Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same
ES2500053T3 (es) 2007-03-09 2014-09-29 Chelsea Therapeutics, Inc. Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
WO2008112773A2 (en) 2007-03-12 2008-09-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
US20080226715A1 (en) 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
DE102007014286A1 (de) 2007-03-19 2008-09-25 Universität Tübingen Fluorsubstituierte Amphetamine und Amphetaminderivate und deren Verwendung
CN102014995B (zh) 2007-03-30 2015-05-13 菲利普莫里斯生产公司 用于输送药剂的装置和方法
AT505086B1 (de) 2007-04-02 2009-06-15 Planta Naturstoffe Vertriebsge Pharmazeutisches mittel gegen juckreiz und juckreizbedingten schmerz
WO2008122990A1 (en) 2007-04-04 2008-10-16 Almet Corporation Limited Compacting upflow extractor and method of using it
WO2008128193A1 (en) 2007-04-12 2008-10-23 Rutgers, The State University Of New Jersey Biodegradable polyanhydrides with natural bioactive molecules
EP2062903A1 (en) 2007-04-18 2009-05-27 Teva Pharmaceutical Industries Ltd. Statin intermediates and process for the preparation of statins
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
JP2011500512A (ja) 2007-07-31 2011-01-06 リメリック バイオファーマ，インコーポレイティド リン酸化ピロン類似体および方法
US20090036468A1 (en) 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
FR2919861A1 (fr) 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate d'isopranol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
AU2016208412A1 (en) 2007-08-06 2016-08-18 Biotie Therapies, Inc. Methods for treating dependence
EP3251670A1 (en) 2007-08-06 2017-12-06 Biotie Therapies, Inc. Methods for treating dependence
JP5358571B2 (ja) 2007-08-07 2013-12-04 プロサリク リミテッド セロトニン作動性調節因子としての１，２，４−トリアゾール誘導体
US8067028B2 (en) 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
JP5599712B2 (ja) 2007-10-05 2014-10-01 インターフェース バイオロジクス，インコーポレーテッド オリゴフッ素化架橋ポリマーおよびそれの使用
WO2009049215A1 (en) 2007-10-10 2009-04-16 Wake Forest University Health Sciences Methods to reduce the effects of sleep deprivation
WO2009055001A2 (en) 2007-10-23 2009-04-30 Fred Hutchinson Cancer Research Center Methods of treating aging and methods of screening candidate agents therefor
WO2009061436A1 (en) 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound
DE102007063210A1 (de) 2007-12-20 2009-06-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung von Phantomphänomenen
WO2009079765A1 (en) 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
US20090176792A1 (en) 2008-01-07 2009-07-09 Auspex Pharmaceuticals, Inc. Substituted dibenzhydrylpiperazines
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
WO2009091605A2 (en) 2008-01-17 2009-07-23 Health Innovations, Llc Taste titration therapies
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
KR20200075044A (ko) * 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8329663B2 (en) 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
WO2009097596A1 (en) 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
CA2713879C (en) 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
AU2009214724A1 (en) 2008-02-11 2009-08-20 Organix Inc. Indole compounds and methods of use thereof
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
JP2011515433A (ja) 2008-03-26 2011-05-19 ロンザ リミテッド エチニルシクロプロパンの合成方法
US20170276676A1 (en) 2008-03-27 2017-09-28 Gus J. Slotman System for assessing drug efficacy and response of a patient to therapy
WO2009118763A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
US20090252786A1 (en) 2008-03-31 2009-10-08 Christoph Hanz Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor
EP2106799A1 (en) 2008-03-31 2009-10-07 OWEN Holding LTD Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
FR2930147B1 (fr) 2008-04-18 2013-02-08 Flamel Tech Sa Forme orale solide dotee d'un double profil de liberation
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
US20110086063A1 (en) 2008-06-04 2011-04-14 Cornell University Vaccines for prevention and treatment of addiction
US10388179B2 (en) 2008-06-18 2019-08-20 Accenture Global Solutions Limited Analytics platform
EP2285362B1 (en) 2008-06-19 2017-08-09 LTS LOHMANN Therapie-Systeme AG Composition for transdermal delivery of cationic active agents
EP2313037A1 (en) 2008-06-30 2011-04-27 Oron Zachar Dermal application of vasoconstrictors
US9642819B2 (en) 2008-07-10 2017-05-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
WO2010006249A1 (en) 2008-07-10 2010-01-14 Tyrx Pharma, Inc. Sustained release formulations of psychoactive drugs
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
FR2936710B1 (fr) 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
WO2010123577A2 (en) 2009-04-24 2010-10-28 Galenea Corp. Compositions and methods for evaluating cognitive deficits
CA2763172A1 (en) 2009-05-26 2010-12-02 David Hackett Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
US20110306596A1 (en) 2009-07-27 2011-12-15 Auspex Pharmaceuticals, Inc. Benzazepine inhibitors of gamma-secretase
US20120302590A1 (en) 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
US20110038915A1 (en) 2009-08-14 2011-02-17 Eduardo Jose Gonzalez Chewing Gum Formula for Enhancing Psycho-Spirituality
WO2011028875A1 (en) 2009-09-03 2011-03-10 Wake Forest University Health Sciences Immunogenic conjugates for producing immune responses to drugs of abuse and methods of use
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
US20120282299A1 (en) 2009-10-16 2012-11-08 Soazig Claude Marie Delamarre Coatings comprising bis-(alpha-amino-diol-diester) containing polyesteramide
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
EP2490677A2 (en) 2009-10-19 2012-08-29 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
CN102933658A (zh) 2009-12-18 2013-02-13 界面生物公司 从自组装涂层局部递送药物
JP5792748B2 (ja) 2010-02-06 2015-10-14 タール ファーマシューティカルズ，インコーポレイテッド 結晶化法及びバイオアベイラビリティ
US20110217289A1 (en) 2010-03-05 2011-09-08 Basf Se Melt-Coated Dosage Forms
WO2011109809A2 (en) 2010-03-05 2011-09-09 New Agriculture, Inc A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
EP2547362B1 (en) 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011138142A1 (en) 2010-05-07 2011-11-10 Ecole Polytechnique Federale De Lausanne (Epfl) Compositions and use of sulfasalazine
AU2011250962B2 (en) 2010-05-10 2015-09-03 Gfbiochemicals Limited Personal care formulations containing alkyl ketal esters and methods of manufacture
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
JP2012020991A (ja) 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CA2806232A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012022928A2 (en) 2010-08-20 2012-02-23 Heptares Therapeutic Ltd Biological materials and uses thereof
WO2012074588A2 (en) 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US20120129834A1 (en) 2010-09-17 2012-05-24 Buck Institute For Research On Aging Serotonin receptor antagonists for use in the treatment of huntington's disease
WO2012039660A1 (en) 2010-09-20 2012-03-29 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
CA2816595C (en) 2010-10-07 2018-11-27 Eaglepharma Pty Ltd Combination therapy for the treatment of depression and other non-infectious diseases
EP2629615B1 (en) 2010-10-22 2018-10-10 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
TR201808178T4 (tr) 2010-11-15 2018-07-23 Neuroderm Ltd Aktif ajanların transdermal dağıtımı için bileşimler.
EP2649443A2 (en) 2010-12-06 2013-10-16 Ramot at Tel-Aviv University Ltd Methods and kits for detection of drugs
EP3834869B1 (en) 2010-12-22 2024-06-05 Syqe Medical Ltd. System for drug delivery
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
FR2971423B1 (fr) 2011-02-15 2014-01-10 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
CN103502817B (zh) 2011-03-28 2016-01-20 前视红外系统股份有限公司 包括药物的分析物的检测方法
US8742096B2 (en) 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
TWI636784B (zh) 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
US20120282255A1 (en) 2011-04-07 2012-11-08 Greg Plucinski Methods and compositions for the treatment of alcoholism and alcohol dependence
KR20120128440A (ko) 2011-05-17 2012-11-27 삼성전자주식회사 표적 물질 검출용 키트 및 이를 이용한 표적 물질 검출 방법
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
KR20140042868A (ko) 2011-06-23 2014-04-07 맵 파마슈티컬스, 인코포레이티드 신규한 플루오로에르골린 유사체
US9040520B2 (en) 2011-09-15 2015-05-26 Demerx, Inc. Noribogaine salt ansolvates
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
FR2983409B1 (fr) 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
IN2014CN04160A (https=) 2011-12-08 2015-07-17 Demerx Inc
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
EP2788356A4 (en) 2011-12-09 2015-10-21 Demerx Inc SULFATESTER FROM NORIBOGAIN
EP2607352A1 (en) 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
EP2610245A1 (en) 2011-12-28 2013-07-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-sulfonamides for treatment of psychiatric disorders
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
EP2807167A4 (en) 2012-01-25 2016-01-20 Demerx Inc INDOIND AND BENZO FURANKED ISOCHINUCLIDEN DERIVATIVES AND METHOD FOR THE MANUFACTURE THEREOF
WO2013112163A1 (en) 2012-01-25 2013-08-01 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US20130295170A1 (en) 2012-05-03 2013-11-07 Kydes Pharmaceuticals Llc Compositions for control of drug abuse
US20130295016A1 (en) 2012-05-07 2013-11-07 David J. Gerber Signatures of electroencephalographic oscillations
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US8784835B2 (en) 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
US20150196533A1 (en) 2012-07-02 2015-07-16 The General Hospital Corporation Method for concurrent treatment of pain and depression
EP2690102A1 (en) 2012-07-24 2014-01-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bicyclic aza-amides for treatment of psychiatric disorders
EP2884962B1 (en) 2012-08-17 2019-05-01 Smartek International LLC Preparation of desiccated liposomes for use in compressible delivery systems
CA2882870C (en) 2012-08-24 2020-12-15 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US20140066881A1 (en) 2012-08-31 2014-03-06 Zoll Medical Corporation Cardiac resuscitation methods and kits
US20140100282A1 (en) 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
US20150231300A1 (en) 2012-10-28 2015-08-20 Peritech Pharma Ltd. Pharmaceutical liquid adhesive compositions for treatment of anorectal disorders
WO2014078857A1 (en) 2012-11-19 2014-05-22 Regents Of The University Of Minnesota Ergoline derivatives as dopamine receptor modulators
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US10555916B2 (en) 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
US20140294923A1 (en) 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014140925A2 (en) 2013-03-10 2014-09-18 Peritech Pharma Ltd. Topical compositions and methods of treatment of topical disorders
US20140288454A1 (en) 2013-03-14 2014-09-25 Pulmonary Analytics Method For Using Exhaled Breath to Determine the Presence of Drug
WO2014146082A1 (en) 2013-03-15 2014-09-18 Bhl Patent Holdings Llc Materials and methods for treating neuropathies and related disorders including those involving a keystone nerve
CA2942638C (en) 2013-03-15 2026-03-10 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
BR112015023116A2 (pt) 2013-03-15 2017-07-18 Melior Discovery Inc composto, composição, formulação para administração oral, método de tratamento de um distúrbio, e, uso de um composto
WO2014142938A1 (en) 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014176556A1 (en) 2013-04-26 2014-10-30 Express Diagnostics International, Inc. Portable testing system for detecting selected drugs or compounds in non-controlled environments
WO2014186623A2 (en) 2013-05-17 2014-11-20 Biomed Valley Discoveries Methods and compositions for the treatment of a chagas disease
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
CA2817728A1 (en) 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
US20160128944A1 (en) 2013-06-04 2016-05-12 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
US20140364367A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
EP2818177A1 (en) 2013-06-24 2014-12-31 Celica, D.O.O. Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states
CN105338974A (zh) 2013-07-03 2016-02-17 阿库拉制药公司 阻止滥用的方法和组合物
CN105473545B (zh) 2013-07-08 2017-08-04 奥斯拜客斯制药有限公司 二羟苯基神经递质化合物、组合物以及方法
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CA2918223A1 (en) * 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US10098893B2 (en) 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
US9474481B2 (en) 2013-10-22 2016-10-25 Mindstrong, LLC Method and system for assessment of cognitive function based on electronic device usage
US9420970B2 (en) 2013-10-22 2016-08-23 Mindstrong, LLC Method and system for assessment of cognitive function based on mobile device usage
MX2016005477A (es) 2013-10-31 2016-08-03 Cima Labs Inc Formas de dosificacion disuasivas del abuso.
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
TW201605856A (zh) 2013-11-01 2016-02-16 艾尼納製藥公司 ５－ＨＴｃ受體促效劑
CN103549133A (zh) 2013-11-05 2014-02-05 杨剑 有机猪牧草饲料
CN103535561A (zh) 2013-11-05 2014-01-29 杨剑 饲养大猪用的牧草饲料
CN103751943B (zh) 2014-01-13 2020-10-13 湖北及安盾消防科技有限公司 一种含有含氮类有机化合物的灭火组合物
AU2014379612A1 (en) 2014-01-24 2016-08-11 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CN103773056B (zh) 2014-01-24 2015-11-18 山东大学 高脆性透明类岩石材料试件制备方法
CA2978537C (en) 2014-03-03 2023-10-24 Demerx, Inc. Therapeutic uses of ibogaine and related compounds
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
EP3151906B1 (en) 2014-06-03 2019-12-11 Pop Test Abuse Deterrent Technology LLC Drug device configured for wireless communication
US10202426B2 (en) 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US10231651B2 (en) 2014-09-25 2019-03-19 Bae Systems Information And Electronic Systems Integration Inc. Gait authentication system and method thereof
US10058253B2 (en) 2014-11-11 2018-08-28 Zenmark, Llc System, method, and article for heart rate variability monitoring
WO2016145193A1 (en) 2015-03-10 2016-09-15 Eleusis Benefit Corporation, Pbc Lsd for the treatment of alzheimer's disease
EP3275448B1 (en) 2015-03-24 2025-10-29 Kyowa Kirin Co., Ltd. Nucleic acid-containing lipid nanoparticles
US10254298B1 (en) 2015-03-25 2019-04-09 National Technology & Engineering Solutions Of Sandia, Llc Detection of metabolites for controlled substances
ES2882588T3 (es) * 2015-03-31 2021-12-02 Turtle Bear Holdings Llc Actividad antiviral de setas medicinales y sus constituyentes activos
MX373319B (es) 2015-04-27 2020-06-13 Arena Pharm Inc Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.
CA2952818A1 (en) 2015-05-01 2016-11-10 Eran Eilat Compositions for the treatment of epistaxis
US20180147142A1 (en) 2015-05-19 2018-05-31 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
WO2016187277A1 (en) 2015-05-19 2016-11-24 Joseph Robert Knight Method for isolation of alkaloids and amino acids, and compositions containing isolated alkaloids and amino acids
US9737759B2 (en) 2015-07-17 2017-08-22 Genesant Technologies, Inc. Automatic application-based exercise tracking system and method
MA42527A (fr) 2015-07-31 2021-04-07 Arena Pharm Inc Agonistes de récepteur 5-ht2c et compositions et procédés d'utilisation
US9614734B1 (en) 2015-09-10 2017-04-04 Pearson Education, Inc. Mobile device session analyzer
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
EA038219B1 (ru) 2016-08-19 2021-07-26 Арена Фармасьютикалз, Инк. Агонисты рецептора 5-ht2c и композиции, а также способ их применения
US10596378B2 (en) 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US20180195455A1 (en) 2017-01-12 2018-07-12 GM Global Technology Operations LLC Engine combustion phasing control during transient state
NL2018190B1 (en) * 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
EP3576755A4 (en) 2017-02-02 2020-12-02 McMaster University BICARBONATE AS A POTENTIALIZER OF ANTIMICROBIAL AGENTS
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
WO2018145219A1 (es) 2017-02-09 2018-08-16 Serani Mostazal Jorge Composición farmaceutica para la prevención y tratamiento de las adicciones a traves de un contracondicionamiento aversivo
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
CN108619214A (zh) 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
NZ757591A (en) 2017-03-30 2026-03-27 Ojai Energetics Pbc Methods and compositions for enhancing health
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
US20190246591A1 (en) 2017-05-31 2019-08-15 Insectergy, Llc Insect and cannabis production systems and methods
US20180343812A1 (en) 2017-05-31 2018-12-06 Insectergy, Llc Cannabis farming systems and methods
EP3629899A4 (en) 2017-06-02 2021-04-21 Northwestern University Thin, soft, skin-mounted microfluidic networks for detection and analysis of targets of interest in sweat
CN107252080A (zh) 2017-07-12 2017-10-17 沈建国 一种麻菇酱油的配方
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
JP2021500948A (ja) 2017-10-19 2021-01-14 エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド サイケデリック薬剤療法の安全性を向上させる方法およびシステム
MA50786A (fr) 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
US10703325B2 (en) 2017-11-27 2020-07-07 Autoliv Asp, Inc. Multi-chambered side airbag assemblies
EP3720506A4 (en) 2017-12-04 2021-09-29 Lecouteur, David COMPOSITIONS AND METHODS FOR MODULATING THE WINDOWS OF HEPATIC ENDOTHELIAL CELLS
FI128750B (en) 2017-12-21 2020-11-30 Helsingin Yliopisto Methods for determining the therapeutic effect of fast-acting antidepressants and related individual antidepressant therapy
WO2019144140A1 (en) 2018-01-22 2019-07-25 CyPhi LLC Bio-mimetic formulation
WO2019161050A1 (en) 2018-02-18 2019-08-22 Akili Interactive Labs, Inc. Cognitive platform including computerized elements coupled with a therapy for mood disorder
MX2020009254A (es) 2018-03-08 2021-01-15 New Atlas Biotechnologies Llc Procesos para la produccion de triptaminas.
FI129102B (en) 2018-03-19 2021-07-15 Teknologian Tutkimuskeskus Vtt Oy Heterological production of psilosybin
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
CA3148256A1 (en) 2018-06-21 2019-12-26 Robert John Petcavich Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
EP3829640A4 (en) 2018-08-01 2022-05-25 McMaster University Methods for inhibiting microbe growth
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
US11337937B2 (en) * 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction
WO2020053196A1 (en) 2018-09-10 2020-03-19 Universität Basel Method for the biocatalytic alkylation of a substrate
WO2020142259A1 (en) 2019-01-04 2020-07-09 Apollo Neuroscience, Inc. Systems and methods of wave generation for transcutaneous vibration
MA54877A (fr) 2019-01-30 2021-12-08 Diamond Therapeutics Inc Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20210015738A1 (en) 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
EP4178569A4 (en) 2020-07-10 2024-07-31 Eleusis Therapeutics US, Inc. Method of treatment for psilocybin or psilocin infusion
EP4009026B1 (en) 2020-12-02 2024-09-18 Volvo Truck Corporation An air-actuated vehicle system and a method of detecting leakage in an air-actuated vehicle system
TW202304466A (zh) 2021-03-30 2023-02-01 英商康派斯開拓者公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法
WO2023086252A1 (en) 2021-11-09 2023-05-19 Compass Pathfinder Limited Treatment of treatment resistant depression with psilocybin
AU2023319280A1 (en) 2022-08-05 2025-03-20 Mindset Pharma Inc. 3-ethylamino-indole dimers as serotonergic agents useful for the treatment of disorders related thereto

Also Published As

Publication number Publication date
AU2020259406B2 (en) 2026-04-09
AU2020259406A1 (en) 2021-11-04
US12611418B2 (en) 2026-04-28
US12433904B2 (en) 2025-10-07
JP2025036703A (ja) 2025-03-14
JP2022529781A (ja) 2022-06-24
CN114206349A (zh) 2022-03-18
AU2020257625B2 (en) 2026-04-09
EP3955936A1 (en) 2022-02-23
CA3138008A1 (en) 2020-10-22
KR20220009955A (ko) 2022-01-25
US12447164B2 (en) 2025-10-21
WO2020212951A1 (en) 2020-10-22
TW202103699A (zh) 2021-02-01
WO2020212948A1 (en) 2020-10-22
US20250302851A1 (en) 2025-10-02
US20230124137A1 (en) 2023-04-20
CA3138094A1 (en) 2020-10-22
US11865126B2 (en) 2024-01-09
CA3138100A1 (en) 2020-10-22
EP3955919A1 (en) 2022-02-23
US11564935B2 (en) 2023-01-31
US20230330117A1 (en) 2023-10-19
WO2020212952A1 (en) 2020-10-22
JP2025039633A (ja) 2025-03-21
KR20220009954A (ko) 2022-01-25
JP2025036702A (ja) 2025-03-14
US20220169668A1 (en) 2022-06-02
AU2020258086A1 (en) 2021-11-11
AU2020257625A1 (en) 2021-11-04
EP3955918A1 (en) 2022-02-23
US20230000883A1 (en) 2023-01-05
CN113993522A (zh) 2022-01-28
US12377112B2 (en) 2025-08-05
AU2020258086B2 (en) 2026-03-05
US11738035B2 (en) 2023-08-29
US20240252521A1 (en) 2024-08-01
US20250367223A1 (en) 2025-12-04
US20220088041A1 (en) 2022-03-24
CN113993523A (zh) 2022-01-28
JP2022529476A (ja) 2022-06-22
JP2022529353A (ja) 2022-06-21
US20230023092A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
US12611418B2 (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CA3240774A1 (en) Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
HK40068334A (en) Treatment of depression and other various disorders with psilocybin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000